Company Focus

Novo Nordisk

Latest Novo Nordisk News

Study shows benefits and risks from GLP-1RAs
Pharmaceutical
A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), which are increasingly being used to treat diabetes and obesity.   21 January 2025


Latest News & Features of interest to Novo Nordisk

Latest In Brief for Novo Nordisk

Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jeraygo (aprocitentan) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately controlled by at least three other medicines (also known as resistant hypertension).   17 January 2025

Latest Related Ones To Watch News

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered under Medicare Part D for price negotiations. US antiviral giant Gilead Sciences is broadening its therapeutics focus with a deal for LEO Pharma’s small molecule oral STAT6 program in the area of inflammatory diseases.US healthcare giant Johnson & Johnson announced its planned $14.6 billion acquisition of Intra-Cellular Therapies, along with its already marketed CNS drug Caplyta. USA-based Keros Therapeutics revealed it is termination another Phase II study of its pulmonary arterial hypertension (PAH) candidate cibotercept. Also, Italy’s Newron Pharmaceuticals out-licensed its CNS drug evenamide to South Korea’s Myung In Pharma, having just recently licensed the drug to EA Pharma, a unit of Japan’s Eisai.   19 January 2025

More in M&A >


Related Ones to Watch Companies

Reset all filters
Refine Search